C4T to Host Webcast on September 20, 2025 at 3 pm ETWATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, ...

Core Insights - C4 Therapeutics, Inc. reported compelling overall response rates for cemsidomide in multiple myeloma, with a 50% overall response rate (ORR) at the highest dose of 100 µg, including one patient achieving a minimal residual disease negative complete response [1][5] - The company plans to prioritize the development of cemsidomide and expects FDA feedback by mid-2025 to support the next phase of development in early 2026 [1][2] - C4T's financial position remains strong, with cash, cash equivalents, and marketable securities totaling $234.7 million as of March 31, 2025, expected to fund operations into 2027 [1][15] Cemsidomide Development - Cemsidomide's Phase 1 trial in multiple myeloma has shown a 50% ORR at the 100 µg dose level, with 80% of patients having prior CAR-T or T-cell engager therapy [5] - At the 75 µg dose level, an ORR of 40% was achieved [5] - The drug is well-tolerated with manageable neutropenia, and the ongoing Phase 1 trial for non-Hodgkin's lymphoma is still in progress [5] Financial Performance - Total revenue for Q1 2025 was $7.2 million, up from $3.0 million in Q1 2024, primarily due to collaborations with Merck KGaA and Roche [9] - Research and development expenses increased to $27.1 million in Q1 2025 from $22.5 million in Q1 2024, reflecting higher clinical trial costs [10] - General and administrative expenses decreased to $9.3 million in Q1 2025 from $10.3 million in Q1 2024 due to reduced personnel costs [11] Strategic Decisions - The company has decided not to advance CFT1946 beyond the current Phase 1 trial and will seek partnership opportunities for the BRAF program [14][18] - C4T continues to advance its internal research pipeline, focusing on targets with a strong degrader rationale applicable to various therapeutic areas [14] Upcoming Milestones - C4T plans to present data from the completed cemsidomide Phase 1 dose escalation in multiple myeloma in Q3 2025 and in non-Hodgkin's lymphoma in Q4 2025 [14] - The company aims to initiate the next phase of clinical development for cemsidomide in early 2026 [14]